Collegium Pharma (NASDAQ: COLL) reported Q4 EPS of $1.09, in-line with the analyst estimate of $1.09. Revenue for the quarter came in at $129.6 million versus the consensus estimate of $125.2 million.

GUIDANCE:

Collegium Pharma sees FY2023 revenue of $565-580 million, versus the consensus of $569.7 million.

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.